ICON Public (ICLR) Projected to Post Quarterly Earnings on Wednesday

ICON Public (NASDAQ:ICLR) is expected to be releasing its Q1 2025 earnings data after the market closes on Wednesday, April 30th. Analysts expect ICON Public to post earnings of $3.17 per share and revenue of $2.03 billion for the quarter.

ICON Public (NASDAQ:ICLR) last announced its quarterly earnings results on Wednesday, February 19th. The medical research company reported $3.42 earnings per share for the quarter, topping the consensus estimate of $3.41 by $0.01. The company had revenue of $2.04 billion for the quarter, compared to the consensus estimate of $2.04 billion. ICON Public had a return on equity of 11.81% and a net margin of 9.56%. On average, analysts expect ICON Public to post $13 EPS for the current fiscal year and $15 EPS for the next fiscal year.

ICON Public Price Performance

Shares of ICLR opened at $145.00 on Tuesday. The business’s 50-day moving average is $169.25 and its two-hundred day moving average is $198.88. The company has a market capitalization of $11.71 billion, a P/E ratio of 15.22, a P/E/G ratio of 1.86 and a beta of 1.24. The company has a debt-to-equity ratio of 0.36, a quick ratio of 1.34 and a current ratio of 1.26. ICON Public has a fifty-two week low of $133.28 and a fifty-two week high of $347.72.

Analysts Set New Price Targets

Several research firms recently issued reports on ICLR. Truist Financial lowered their price objective on ICON Public from $262.00 to $208.00 and set a “buy” rating on the stock in a report on Thursday, April 10th. TD Cowen cut ICON Public from a “buy” rating to a “hold” rating and lowered their price objective for the stock from $254.00 to $157.00 in a report on Monday, April 14th. Robert W. Baird decreased their target price on shares of ICON Public from $221.00 to $203.00 and set a “neutral” rating on the stock in a research note on Tuesday, March 4th. William Blair reissued an “outperform” rating on shares of ICON Public in a research note on Tuesday, January 14th. Finally, Citigroup decreased their target price on shares of ICON Public from $290.00 to $215.00 and set a “buy” rating on the stock in a research note on Monday, April 7th. Seven equities research analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $232.67.

ICON Public Company Profile

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.